Tislelizumab plus anlotinib with or without radiotherapy as first-line therapy in advanced hepatocellular carcinoma: a single center, non-randomized retrospective case–control study

Abstract The purpose of this study was to investigate the efficacy and safety of tislelizumab (monoclonal antibody) plus anlotinib (tyrosine kinase inhibitor) with or without radiotherapy in advanced hepatocellular carcinoma (HCC). Ninety patients with advanced HCC were divided into two groups: tisl...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Guishu Wu, Yuhong Liu, Huaxi Fan, Mingyue Rao, Jing Zhang, Jianwen Zhang
Format:	Artigo
Język:	Inglês
Wydane:	Springer 2025-03-01
Seria:	Discover Oncology
Hasła przedmiotowe:	Hepatocellular carcinoma Immune checkpoint inhibitors Immunotherapy Targeted therapy Radiotherapy
Dostęp online:	https://doi.org/10.1007/s12672-025-02171-5
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!